Your browser is no longer supported. Please, upgrade your browser.
RTRX Retrophin, Inc. daily Stock Chart
RTRX [NASD]
Retrophin, Inc.
Index- P/E- EPS (ttm)-2.94 Insider Own0.70% Shs Outstand41.46M Perf Week8.07%
Market Cap594.12M Forward P/E- EPS next Y-2.31 Insider Trans-2.52% Shs Float36.03M Perf Month10.32%
Income-123.60M PEG- EPS next Q-0.65 Inst Own- Short Float10.94% Perf Quarter16.41%
Sales172.40M P/S3.45 EPS this Y-67.60% Inst Trans2.46% Short Ratio8.73 Perf Half Y-27.74%
Book/sh5.73 P/B2.50 EPS next Y32.80% ROA-18.70% Target Price28.57 Perf Year-42.03%
Cash/sh9.82 P/C1.46 EPS next 5Y20.00% ROE-43.90% 52W Range10.87 - 25.53 Perf YTD-36.68%
Dividend- P/FCF- EPS past 5Y-0.80% ROI-18.30% 52W High-43.87% Beta0.86
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin97.00% 52W Low31.83% ATR0.48
Employees214 Current Ratio5.00 Sales Q/Q9.10% Oper. Margin-66.20% RSI (14)69.01 Volatility3.34% 3.42%
OptionableYes Debt/Eq0.82 EPS Q/Q36.50% Profit Margin-71.70% Rel Volume1.18 Prev Close13.83
ShortableYes LT Debt/Eq0.82 EarningsJan 29 AMC Payout- Avg Volume451.48K Price14.33
Recom1.50 SMA206.98% SMA5015.39% SMA200-16.15% Volume534,598 Change3.62%
Apr-22-19Initiated Barclays Overweight
Nov-19-18Initiated Nomura Buy $57
Aug-17-18Initiated Canaccord Genuity Buy $36
Nov-02-15Initiated JMP Securities Mkt Outperform $30
Jun-04-15Reiterated Deutsche Bank Buy $52 → $55
May-15-15Initiated Avondale Mkt Outperform
Apr-28-15Initiated Deutsche Bank Buy $50
Dec-12-19 10:54AM  Did You Manage To Avoid Retrophin's (NASDAQ:RTRX) 46% Share Price Drop? Simply Wall St.
Dec-10-19 03:57PM  These Hedge Funds Cashed Out Of Retrophin Inc (RTRX) Too Early Insider Monkey
Nov-15-19 02:13PM  Edited Transcript of RTRX earnings conference call or presentation 30-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 04:30PM  Retrophin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
Nov-08-19 10:04AM  The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co Zacks +6.02%
Nov-07-19 10:21AM  Top Ranked Momentum Stocks to Buy for November 7th Zacks
09:17AM  Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks Zacks
Oct-30-19 07:05PM  Retrophin (RTRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Retrophin Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-28-19 06:04PM  Is Retrophin Inc (RTRX) Going To Burn These Hedge Funds ? Insider Monkey
Oct-23-19 10:34AM  Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to Decline Zacks
Oct-16-19 04:30PM  Retrophin to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-11-19 04:05PM  Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019 GlobeNewswire
Oct-01-19 04:30PM  Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer GlobeNewswire
11:31AM  One Thing To Remember About The Retrophin, Inc. (NASDAQ:RTRX) Share Price Simply Wall St.
Sep-26-19 04:30PM  Retrophin to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Aug-28-19 10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
Aug-23-19 07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-22-19 04:33PM  Why Tilray, Splunk, and Retrophin Slumped Today Motley Fool -22.07%
04:15PM  A Risky Drug Didn't Pan Out For This Biotech Shares Hit 3-Year Low Investor's Business Daily
02:00PM  Why Retrophin, Inc. Is Tanking Today Motley Fool
10:42AM  Shkreli-Founded Biotech Seen Ripe for Buying as Shares Tumble Bloomberg
07:59AM  Retrophin's stock plunges after late-stage trial for PKAN treatment fails to meet targets MarketWatch
07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
06:32AM  CORRECTED-UPDATE 2-Retrophin scraps nervous system disorder study, shares dive Reuters
06:13AM  Retrophin neurological disorder drug misses late-stage study main goal Reuters
06:00AM  Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN GlobeNewswire
Aug-19-19 09:55AM  Implied Volatility Surging for Retrophin (RTRX) Stock Options Zacks
Aug-14-19 04:25AM  Edited Transcript of RTRX earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 08:25AM  Retrophin (RTRX) Q2 2019 Earnings Call Transcript Motley Fool -13.15%
Aug-06-19 06:45PM  Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
Jul-31-19 04:30PM  Retrophin to Present at Canaccord Genuitys 39th Annual Growth Conference GlobeNewswire
09:59AM  Is Retrophin (NASDAQ:RTRX) A Risky Investment? Simply Wall St.
Jul-30-19 10:38AM  Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-23-19 04:30PM  Retrophin to Report Second Quarter 2019 Financial Results GlobeNewswire
Jul-18-19 10:33AM  Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for Zacks
Jun-29-19 08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-28-19 06:15AM  U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction Reuters
Jun-25-19 02:30PM  An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued Simply Wall St.
02:28PM  Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount? Simply Wall St.
Jun-21-19 09:06AM  Shkreli and Retrophin resolve 'all outstanding disputes' American City Business Journals
Jun-20-19 05:13PM  Martin Shkreli settles all litigation with his former company Retrophin Reuters
04:33PM  Martin Shkreli settles all litigation with his former company Retrophin Reuters
Jun-18-19 04:30PM  Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome GlobeNewswire
Jun-03-19 12:33PM  Is Retrophin, Inc.'s (NASDAQ:RTRX) Balance Sheet A Threat To Its Future? Simply Wall St.
May-31-19 05:41PM  From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 million Reuters
02:55PM  'Pharma bro' Martin Shkreli sues Retrophin directors, ex-general counsel for more than $30 million from prison in Pennsylvania CNBC
May-30-19 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
May-13-19 06:30PM  Edited Transcript of RTRX earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
08:00AM  Retrophin Appoints Sandra E. Poole to Board of Directors GlobeNewswire
May-08-19 03:24PM  Retrophin (RTRX) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:35PM  Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:26PM  Retrophin: 1Q Earnings Snapshot Associated Press
04:01PM  Retrophin Reports First Quarter 2019 Financial Results GlobeNewswire
02:30PM  Retrophin, Inc. to Host Earnings Call ACCESSWIRE
10:55AM  Heres What Hedge Funds Think About Retrophin Inc (RTRX) Insider Monkey
Apr-30-19 10:32AM  Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for Zacks
09:30AM  2 Healthcare Stocks With Jaw-Dropping Growth Potential Motley Fool
Apr-26-19 12:19PM  The Retrophin (NASDAQ:RTRX) Share Price Is Up 41% And Shareholders Are Holding On Simply Wall St.
Apr-23-19 04:30PM  Retrophin to Report First Quarter 2019 Financial Results GlobeNewswire
Mar-24-19 08:13AM  Edited Transcript of RTRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-14-19 11:20AM  Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
Mar-07-19 12:53PM  Will Retrophin, Inc.s (NASDAQ:RTRX) Earnings Grow In The Next Couple Of Years? Simply Wall St.
Mar-06-19 08:15AM  Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-05-19 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
Feb-28-19 08:00AM  Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers GlobeNewswire
Feb-26-19 10:01PM  Retrophin Inc (RTRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
02:30PM  Retrophin, Inc. to Host Earnings Call ACCESSWIRE
Feb-14-19 04:30PM  Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-12-19 04:30PM  Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-08-19 08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-04-19 07:35AM  Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-17-19 06:55AM  Citron Says Ligand Has 80% Downside in Explosive Note Investopedia
Jan-07-19 07:00AM  Retrophin Provides Corporate Update and 2019 Outlook GlobeNewswire
Jan-04-19 07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:30PM  Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer GlobeNewswire
Jan-02-19 04:30PM  Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-27-18 08:00AM  Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy GlobeNewswire
Dec-20-18 08:00AM  Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN GlobeNewswire
Dec-14-18 03:13AM  Retrophin Inc (RTRX) Hedge Funds Are Snapping Up Insider Monkey
Dec-05-18 09:32AM  How Does Retrophin Inc (NASDAQ:RTRX) Affect Your Portfolio Volatility? Simply Wall St.
Nov-28-18 04:30PM  Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire +5.58%
08:50AM  Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-12-18 07:00AM  Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria GlobeNewswire
Nov-08-18 01:17PM  Edited Transcript of RTRX earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
12:36PM  Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript Motley Fool
Nov-07-18 04:30PM  Retrophin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-01-18 06:50PM  Retrophin (RTRX) Reports Q3 Loss, Lags Revenue Estimates Zacks +7.95%
05:46PM  Retrophin: 3Q Earnings Snapshot Associated Press
04:01PM  Retrophin Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-29-18 08:44PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders Business Wire
Oct-26-18 09:18PM  Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis GlobeNewswire
Oct-25-18 04:01PM  Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology GlobeNewswire
Oct-19-18 09:10AM  New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-18-18 04:30PM  Retrophin to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-05-18 04:01PM  Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018 GlobeNewswire
Oct-03-18 04:30PM  Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses GlobeNewswire
Sep-27-18 04:30PM  Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy GlobeNewswire
Sep-17-18 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. The company has a cooperative research and development agreement with National Center for the identification and development of therapeutics for Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorNov 29Sale13.915,00069,553250,966Nov 29 09:27 PM
Rosenberg Noah L.Chief Medical OfficerJul 31Sale20.071,25025,08813,500Jul 31 09:15 PM
Rosenberg Noah L.Chief Medical OfficerJul 30Sale19.821,25024,77514,750Jul 31 09:15 PM
Clague LauraChief Financial OfficerMay 16Sale18.711,25023,38813,500May 16 09:37 PM
McFarlane Neil F.Chief Operating OfficerMay 16Sale18.7198418,41126,988May 16 09:37 PM
Clague LauraChief Financial OfficerMay 15Sale17.781,25022,22514,750May 16 09:37 PM
McFarlane Neil F.Chief Operating OfficerMay 15Sale17.7898417,49627,972May 16 09:37 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 15Sale17.7681214,42118,185May 16 09:36 PM
ASELAGE STEVEDirectorMay 15Sale17.821,83832,753255,966May 16 09:34 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 15Sale17.715259,29819,508May 16 09:35 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 14Sale17.7881314,45518,997May 16 09:36 PM
ASELAGE STEVEDirectorMay 14Sale17.791,83832,698257,804May 16 09:34 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 14Sale17.755259,31920,033May 16 09:35 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 19Sale21.521,25026,90013,810Feb 20 07:58 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 15Sale21.441,25026,80015,060Feb 20 07:58 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryFeb 12Sale21.5088419,00614,558Feb 13 08:50 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 12Sale21.5099221,32816,007Feb 13 08:49 PM
Clague LauraChief Financial OfficerFeb 12Sale21.501,01621,84410,000Feb 13 08:49 PM
ASELAGE STEVEChief Executive OfficerFeb 12Sale21.501,06522,898257,642Feb 13 08:47 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryFeb 11Sale21.3888518,92115,442Feb 13 08:50 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 11Sale21.3899321,23016,999Feb 13 08:49 PM
Clague LauraChief Financial OfficerFeb 11Sale21.381,01721,74311,016Feb 13 08:49 PM
ASELAGE STEVEChief Executive OfficerFeb 11Sale21.381,06522,770258,707Feb 13 08:47 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 09Sale23.8275017,86516,327Jan 09 07:43 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 08Sale24.0975018,06817,077Jan 09 07:43 PM
ASELAGE STEVEChief Executive OfficerDec 21Sale21.796,188134,829259,772Dec 21 08:20 PM
Clague LauraChief Financial OfficerDec 21Sale21.833,75081,86012,033Dec 21 08:19 PM
McFarlane Neil F.Chief Operating OfficerDec 20Sale22.3211,125248,33328,956Dec 21 08:21 PM
ASELAGE STEVEChief Executive OfficerDec 20Sale21.976,188135,958265,960Dec 21 08:20 PM
Clague LauraChief Financial OfficerDec 20Sale22.083,75082,80515,783Dec 21 08:19 PM